A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease

M. Bouchentouf, K. Forner, J. Cuerquis, M. R. Boulassel, J. P. Routy, E. K. Waller, A. A. Quyyumi, P. Paradis, E. L. Schiffrin, J. Galipeau

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Endothelial progenitor cells (EPCs) consist of two different subpopulations named early (eEPCs) and late EPCs (lEPCs) that are derived from CD14+ and CD14& circulating cells, respectively. These cells are regularly cultured over fibronectin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). We have developed a new and simplified method for culturing human EPCs obtained from peripheral blood and tested their ability to preserve cardiac function following infarction. We first demonstrated that eEPCs derived from human peripheral blood mononuclear cells (PBMCs) and cultured in EBM-2 medium supplemented with autologous serum (10%) over fibronectincoated surfaces (10 μg/ml) in the presence of IGF-1 (50 ng/ml) only, have a secretome similar to eEPCs cultured under regular conditions with IGF-1, VEGF, EGF, and FGF. Our data also indicate that IGF-1 modulates PBMC secretome in a dose-dependent manner. In another series of experiments, we showed that PBMCs cultured in suspension in bags (S-PBMCs) in basal medium supplemented with fibronectin and IGF-1 secrete significant amounts of stem cell factor (SCF, 31.3 ± 3.1 pg/ml)), hepatocyte growth factor (HGF, 438.6 ± 41.4 pg/ml), soluble tumor necrosis factor receptor 1 (sTNFR1, 127.1 ± 9.9 pg/ml), VEGF (139.3 ± 9.6 pg/ml), and IGF-1 (147.2 ± 46.1 pg/ml) but very low levels of TNF-α (13.4 ± 2.5 pg/ml). S-PBMCs injected intravenously into NOD SCID mice migrated to the injured myocardium, reduced cardiac fibrosis, enhanced angiogenesis, and preserved cardiac function after myocardial infarction (MI) in a manner similar to eEPCs cultured under standard conditions. In conclusion, we show in this study a refined and optimized method for culturing eEPCs. Our data indicate that S-PBMCs are composed of several cell populations including eEPCs and that they secrete high amounts of antiapoptotic, anti-inflammatory, and proangiogenic factors capable of preserving cardiac function following MI.

Original languageEnglish
Pages (from-to)1431-1443
Number of pages13
JournalCell Transplantation
Volume20
Issue number9
DOIs
Publication statusPublished - 2011

Fingerprint

Endothelial cells
Insulin-Like Growth Factor I
Vascular Diseases
Cell culture
Blood Cells
Blood
Vascular Endothelial Growth Factor A
Fibroblast Growth Factors
Fibronectins
Epidermal Growth Factor
Fibroblasts
Myocardial Infarction
Inbred NOD Mouse
Stem Cell Factor
Hepatocyte Growth Factor
SCID Mice
Tumor Necrosis Factor Receptors
Somatomedins
Insulin
Infarction

Keywords

  • Endothelial progenitor cells (EPCs) growth factors culture method angiogenesis myocardial infarction (MI)

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease. / Bouchentouf, M.; Forner, K.; Cuerquis, J.; Boulassel, M. R.; Routy, J. P.; Waller, E. K.; Quyyumi, A. A.; Paradis, P.; Schiffrin, E. L.; Galipeau, J.

In: Cell Transplantation, Vol. 20, No. 9, 2011, p. 1431-1443.

Research output: Contribution to journalArticle

Bouchentouf, M, Forner, K, Cuerquis, J, Boulassel, MR, Routy, JP, Waller, EK, Quyyumi, AA, Paradis, P, Schiffrin, EL & Galipeau, J 2011, 'A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease', Cell Transplantation, vol. 20, no. 9, pp. 1431-1443. https://doi.org/10.3727/096368910X557164
Bouchentouf, M. ; Forner, K. ; Cuerquis, J. ; Boulassel, M. R. ; Routy, J. P. ; Waller, E. K. ; Quyyumi, A. A. ; Paradis, P. ; Schiffrin, E. L. ; Galipeau, J. / A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease. In: Cell Transplantation. 2011 ; Vol. 20, No. 9. pp. 1431-1443.
@article{56c1f0d12dbc4d258e4dd0592a072a72,
title = "A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease",
abstract = "Endothelial progenitor cells (EPCs) consist of two different subpopulations named early (eEPCs) and late EPCs (lEPCs) that are derived from CD14+ and CD14& circulating cells, respectively. These cells are regularly cultured over fibronectin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). We have developed a new and simplified method for culturing human EPCs obtained from peripheral blood and tested their ability to preserve cardiac function following infarction. We first demonstrated that eEPCs derived from human peripheral blood mononuclear cells (PBMCs) and cultured in EBM-2 medium supplemented with autologous serum (10{\%}) over fibronectincoated surfaces (10 μg/ml) in the presence of IGF-1 (50 ng/ml) only, have a secretome similar to eEPCs cultured under regular conditions with IGF-1, VEGF, EGF, and FGF. Our data also indicate that IGF-1 modulates PBMC secretome in a dose-dependent manner. In another series of experiments, we showed that PBMCs cultured in suspension in bags (S-PBMCs) in basal medium supplemented with fibronectin and IGF-1 secrete significant amounts of stem cell factor (SCF, 31.3 ± 3.1 pg/ml)), hepatocyte growth factor (HGF, 438.6 ± 41.4 pg/ml), soluble tumor necrosis factor receptor 1 (sTNFR1, 127.1 ± 9.9 pg/ml), VEGF (139.3 ± 9.6 pg/ml), and IGF-1 (147.2 ± 46.1 pg/ml) but very low levels of TNF-α (13.4 ± 2.5 pg/ml). S-PBMCs injected intravenously into NOD SCID mice migrated to the injured myocardium, reduced cardiac fibrosis, enhanced angiogenesis, and preserved cardiac function after myocardial infarction (MI) in a manner similar to eEPCs cultured under standard conditions. In conclusion, we show in this study a refined and optimized method for culturing eEPCs. Our data indicate that S-PBMCs are composed of several cell populations including eEPCs and that they secrete high amounts of antiapoptotic, anti-inflammatory, and proangiogenic factors capable of preserving cardiac function following MI.",
keywords = "Endothelial progenitor cells (EPCs) growth factors culture method angiogenesis myocardial infarction (MI)",
author = "M. Bouchentouf and K. Forner and J. Cuerquis and Boulassel, {M. R.} and Routy, {J. P.} and Waller, {E. K.} and Quyyumi, {A. A.} and P. Paradis and Schiffrin, {E. L.} and J. Galipeau",
year = "2011",
doi = "10.3727/096368910X557164",
language = "English",
volume = "20",
pages = "1431--1443",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - A novel and simplified method of culture of human blood-derived early endothelial progenitor cells for the treatment of ischemic vascular disease

AU - Bouchentouf, M.

AU - Forner, K.

AU - Cuerquis, J.

AU - Boulassel, M. R.

AU - Routy, J. P.

AU - Waller, E. K.

AU - Quyyumi, A. A.

AU - Paradis, P.

AU - Schiffrin, E. L.

AU - Galipeau, J.

PY - 2011

Y1 - 2011

N2 - Endothelial progenitor cells (EPCs) consist of two different subpopulations named early (eEPCs) and late EPCs (lEPCs) that are derived from CD14+ and CD14& circulating cells, respectively. These cells are regularly cultured over fibronectin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). We have developed a new and simplified method for culturing human EPCs obtained from peripheral blood and tested their ability to preserve cardiac function following infarction. We first demonstrated that eEPCs derived from human peripheral blood mononuclear cells (PBMCs) and cultured in EBM-2 medium supplemented with autologous serum (10%) over fibronectincoated surfaces (10 μg/ml) in the presence of IGF-1 (50 ng/ml) only, have a secretome similar to eEPCs cultured under regular conditions with IGF-1, VEGF, EGF, and FGF. Our data also indicate that IGF-1 modulates PBMC secretome in a dose-dependent manner. In another series of experiments, we showed that PBMCs cultured in suspension in bags (S-PBMCs) in basal medium supplemented with fibronectin and IGF-1 secrete significant amounts of stem cell factor (SCF, 31.3 ± 3.1 pg/ml)), hepatocyte growth factor (HGF, 438.6 ± 41.4 pg/ml), soluble tumor necrosis factor receptor 1 (sTNFR1, 127.1 ± 9.9 pg/ml), VEGF (139.3 ± 9.6 pg/ml), and IGF-1 (147.2 ± 46.1 pg/ml) but very low levels of TNF-α (13.4 ± 2.5 pg/ml). S-PBMCs injected intravenously into NOD SCID mice migrated to the injured myocardium, reduced cardiac fibrosis, enhanced angiogenesis, and preserved cardiac function after myocardial infarction (MI) in a manner similar to eEPCs cultured under standard conditions. In conclusion, we show in this study a refined and optimized method for culturing eEPCs. Our data indicate that S-PBMCs are composed of several cell populations including eEPCs and that they secrete high amounts of antiapoptotic, anti-inflammatory, and proangiogenic factors capable of preserving cardiac function following MI.

AB - Endothelial progenitor cells (EPCs) consist of two different subpopulations named early (eEPCs) and late EPCs (lEPCs) that are derived from CD14+ and CD14& circulating cells, respectively. These cells are regularly cultured over fibronectin-coated surfaces in endothelial basal medium (EBM)-2 supplemented with insulin-like growth factor (IGF-1), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF). We have developed a new and simplified method for culturing human EPCs obtained from peripheral blood and tested their ability to preserve cardiac function following infarction. We first demonstrated that eEPCs derived from human peripheral blood mononuclear cells (PBMCs) and cultured in EBM-2 medium supplemented with autologous serum (10%) over fibronectincoated surfaces (10 μg/ml) in the presence of IGF-1 (50 ng/ml) only, have a secretome similar to eEPCs cultured under regular conditions with IGF-1, VEGF, EGF, and FGF. Our data also indicate that IGF-1 modulates PBMC secretome in a dose-dependent manner. In another series of experiments, we showed that PBMCs cultured in suspension in bags (S-PBMCs) in basal medium supplemented with fibronectin and IGF-1 secrete significant amounts of stem cell factor (SCF, 31.3 ± 3.1 pg/ml)), hepatocyte growth factor (HGF, 438.6 ± 41.4 pg/ml), soluble tumor necrosis factor receptor 1 (sTNFR1, 127.1 ± 9.9 pg/ml), VEGF (139.3 ± 9.6 pg/ml), and IGF-1 (147.2 ± 46.1 pg/ml) but very low levels of TNF-α (13.4 ± 2.5 pg/ml). S-PBMCs injected intravenously into NOD SCID mice migrated to the injured myocardium, reduced cardiac fibrosis, enhanced angiogenesis, and preserved cardiac function after myocardial infarction (MI) in a manner similar to eEPCs cultured under standard conditions. In conclusion, we show in this study a refined and optimized method for culturing eEPCs. Our data indicate that S-PBMCs are composed of several cell populations including eEPCs and that they secrete high amounts of antiapoptotic, anti-inflammatory, and proangiogenic factors capable of preserving cardiac function following MI.

KW - Endothelial progenitor cells (EPCs) growth factors culture method angiogenesis myocardial infarction (MI)

UR - http://www.scopus.com/inward/record.url?scp=80855140448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855140448&partnerID=8YFLogxK

U2 - 10.3727/096368910X557164

DO - 10.3727/096368910X557164

M3 - Article

VL - 20

SP - 1431

EP - 1443

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -